dalteparin has been researched along with mci 9038 in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Heran, CL; Schumacher, WA; Steinbacher, TE | 1 |
| Théroux, P; Xiao, Z | 1 |
| Hirayama, F; Kawasaki, T; Koshio, H; Matsumoto, Y; Sato, K; Taniuchi, Y | 1 |
| Hirayama, F; Hisamichi, N; Kawasaki, T; Koshio, H; Matsumoto, Y; Sato, K; Taniuchi, Y | 1 |
| Maruyama, I; Mohri, M; Sata, M; Sugimoto, E; Suzuki, M; Yamamoto, S | 1 |
| Cho, JH; Dan, T; Kim, HY; Koga, T; Koo, BA; Seo, HS; Yun, CH | 1 |
| Ahmed, S; Karim, A; Mattana, J; Patel, D; Siddiqui, R | 1 |
| Mitome, J; Yamamoto, H | 1 |
| Bates, ER; Mukherjee, D | 1 |
| Bozic, M; Budihna, MV; Cerne, M; Drevensek, G; Peternel, L; Stalc, A; Stegnar, M; Urleb, U; Zega, A | 1 |
| Blombäck, M; He, S; Hjemdahl, P; Li, N | 1 |
| Blain, RC; Lovejoy, AE; Nakagawa, PA; Nugent, DJ; Yonekawa, KE; Young, G | 1 |
| Ansell, JE; Dinwoodey, DL | 1 |
| Bakhos, M; Hoppensteadt, D; Iqbal, O; Jeske, WP; Maddineni, J; Messmore, HL; Prechel, M; Walenga, JM | 1 |
| Buerke, M; Busshardt, M; Ebelt, H; Kaeberich, A; Maegdefessel, L; Plehn, A; Raaz, U; Russ, M; Schlitt, A; Schubert, S; Werdan, K | 1 |
| Medico, CJ; Walsh, P | 1 |
| Bereczky, Z; Boda, Z; Kappelmayer, J; Kerenyi, A; Olah, Z; Szarvas, M | 1 |
| Croci, E; Dentali, F; Giorgi-Pierfranceschi, M; Mumoli, N; Scarpioni, R | 1 |
| Gheysens, O; Goffin, KE; Hoylaerts, MF; Jacquemin, M; Liesenborghs, L; Peerlinck, K; Peetermans, M; Peetermans, WE; Vanassche, T; Verhaegen, J; Verhamme, P; Wijngaerden, EV | 1 |
| Singh Lubana, S; Singh, N; Tsai, HM | 1 |
| Chen, G; Ding, W; Li, K; Ma, D; Nansubuga, F; Wei, J; Weng, D; Wu, P; Yang, J; Yu, R | 1 |
4 review(s) available for dalteparin and mci 9038
| Article | Year |
|---|---|
[Anticoagulant].
Topics: Animals; Anticoagulants; Antithrombins; Arginine; Benzamidines; Chondroitin Sulfates; Dermatan Sulfate; Drug Combinations; Drug Design; Enoxaparin; Extracorporeal Circulation; Guanidines; Heparin; Heparin, Low-Molecular-Weight; Heparinoids; Heparitin Sulfate; Humans; Pipecolic Acids; Protease Inhibitors; Protein C; Recombinant Proteins; Sorption Detoxification; Sulfonamides; Thrombomodulin | 2004 |
Current role of antithrombotic agents in the treatment of acute coronary syndromes.
Topics: Aged; Anticoagulants; Arginine; Blood Platelets; Clinical Trials as Topic; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hirudins; Humans; Middle Aged; Models, Biological; Myocardial Infarction; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Risk; Sulfonamides; Thrombin | 2004 |
Heparins, low-molecular-weight heparins, and pentasaccharides: use in the older patient.
Topics: Aged; Anticoagulants; Arginine; Enoxaparin; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Sulfonamides | 2008 |
Pharmacotherapy in the critically ill obese patient.
Topics: Aminoglycosides; Antithrombins; Arginine; Body Mass Index; Carbapenems; Cephalosporins; Drug Dosage Calculations; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Hypnotics and Sedatives; Lipopeptides; Obesity; Oxazolidinones; Penicillins; Pipecolic Acids; Protein C; Quinolones; Recombinant Proteins; Safety; Sulfonamides; Vancomycin | 2010 |
4 trial(s) available for dalteparin and mci 9038
| Article | Year |
|---|---|
Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Antithrombins; Arginine; Dose-Response Relationship, Drug; Enoxaparin; Female; Heparin; Humans; Male; Middle Aged; P-Selectin; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Platelet Activation; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Sulfonamides | 1998 |
Platelet activity, coagulation, and fibrinolysis during exercise in healthy males: effects of thrombin inhibition by argatroban and enoxaparin.
Topics: Adult; Anticoagulants; Arginine; Blood Coagulation; Blood Platelets; CD11b Antigen; Cross-Over Studies; Double-Blind Method; Enoxaparin; Exercise; Fibrinolysis; Humans; Leukocytes; Male; Pancreatic Elastase; Pipecolic Acids; Platelet Activation; Sulfonamides; Thrombin | 2007 |
Targeting Coagulase Activity in Staphylococcus aureus Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Arginine; Bacteremia; Belgium; Blood Coagulation; Coagulase; Dabigatran; Enoxaparin; Feasibility Studies; Female; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Partial Thromboplastin Time; Pilot Projects; Pipecolic Acids; Prospective Studies; Staphylococcal Infections; Staphylococcus aureus; Sulfonamides; Thrombin; Thrombosis; Time Factors; Treatment Outcome | 2018 |
Efficiency and safety evaluation of prophylaxes for venous thrombosis after gynecological surgery.
Topics: Anticoagulants; Arginine; Endometrial Neoplasms; Female; Gynecologic Surgical Procedures; Heparin, Low-Molecular-Weight; Humans; Injections, Intravenous; Middle Aged; Ovarian Neoplasms; Pipecolic Acids; Postoperative Complications; Risk Factors; Sulfonamides; Uterine Cervical Neoplasms; Venous Thrombosis | 2020 |
13 other study(ies) available for dalteparin and mci 9038
| Article | Year |
|---|---|
Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time.
Topics: Animals; Antithrombins; Arginine; Bleeding Time; Dalteparin; Dose-Response Relationship, Drug; Fibrinolytic Agents; Male; Partial Thromboplastin Time; Pipecolic Acids; Rats; Rats, Sprague-Dawley; Sulfonamides; Thrombosis | 1996 |
YM-60828, a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time.
Topics: Animals; Anticoagulants; Antithrombins; Arginine; Bleeding Time; Dalteparin; Factor Xa Inhibitors; Fibrinolytic Agents; Heparin; Male; Naphthalenes; Pipecolic Acids; Piperidines; Rats; Rats, Sprague-Dawley; Sulfonamides | 1997 |
Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time.
Topics: Animals; Anticoagulants; Arginine; Arteriovenous Shunt, Surgical; Bleeding Time; Blood Proteins; Dalteparin; Factor Xa Inhibitors; Fibrinolytic Agents; Heparin; In Vitro Techniques; Male; Naphthalenes; Partial Thromboplastin Time; Pipecolic Acids; Piperidines; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Sulfonamides; Thrombophlebitis; Thrombosis | 1998 |
Effects of recombinant human soluble thrombomodulin (rhs-TM) on clot-induced coagulation in human plasma.
Topics: Antithrombins; Arginine; Blood Coagulation; Carboxypeptidase B2; Carboxypeptidases; Dalteparin; Dose-Response Relationship, Drug; Enzyme Activation; Fibrinopeptide A; Heparin; Humans; Pipecolic Acids; Protein C; Recombinant Fusion Proteins; Sulfonamides; Thrombelastography; Thrombin; Thrombomodulin | 1998 |
The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis.
Topics: Administration, Oral; Amidines; Animals; Arginine; Azepines; Bleeding Time; Carotid Artery Thrombosis; Dalteparin; Drug Evaluation, Preclinical; Fibrinolytic Agents; Hemorrhage; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Molecular Structure; Pipecolic Acids; Rats; Rats, Sprague-Dawley; Sulfonamides; Thrombin; Vena Cava, Inferior; Venous Thrombosis; Warfarin | 2001 |
Low-molecular weight heparin: treatment failure in a patient with primary antiphospholipid antibody syndrome.
Topics: Adolescent; Anticoagulants; Antiphospholipid Syndrome; Arginine; Arm; Enoxaparin; Female; Folic Acid; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Pipecolic Acids; Pulmonary Embolism; Sulfonamides; Treatment Failure; Treatment Outcome; Venous Thrombosis; Warfarin | 2002 |
Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models.
Topics: Administration, Oral; Animals; Anticoagulants; Arginine; Blood Coagulation Tests; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Fibrinolytic Agents; Injections, Subcutaneous; Male; Nadroparin; Phenylalanine; Pipecolic Acids; Rats; Rats, Wistar; Structure-Activity Relationship; Sulfonamides; Thrombin; Thrombophilia; Vena Cava, Inferior; Venous Thrombosis | 2005 |
Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation.
Topics: Anticoagulants; Antithrombins; Arginine; Blood Coagulation; Drug Evaluation, Preclinical; Elasticity; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Kinetics; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Stress, Mechanical; Sulfonamides; Thrombelastography; Thrombin | 2007 |
Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia.
Topics: Analysis of Variance; Anticoagulants; Antithrombin III; Arginine; Autoantibodies; Enoxaparin; Flow Cytometry; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pipecolic Acids; Platelet Activation; Platelet Aggregation; Platelet Factor 4; Polysaccharides; Rivaroxaban; Sulfonamides; Thiophenes; Thrombocytopenia | 2008 |
The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro.
Topics: Anticoagulants; Antithrombin III; Arginine; Blood Coagulation; Blood Platelets; Cardiac Catheterization; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Fibrin; Heparin; Humans; Male; Peptide Hydrolases; Pipecolic Acids; Stress, Mechanical; Sulfonamides; Thrombin; Thrombosis; Time Factors | 2010 |
Direct thrombin inhibitors and factor xa inhibitors can influence the diluted prothrombin time used as the initial screen for lupus anticoagulant.
Topics: Anticoagulants; Antithrombins; Arginine; Chondroitin Sulfates; Dermatan Sulfate; Enoxaparin; Factor Xa Inhibitors; False Positive Reactions; Fondaparinux; Heparitin Sulfate; Hirudins; Humans; Lupus Coagulation Inhibitor; Mass Screening; Pipecolic Acids; Polysaccharides; Prothrombin Time; Recombinant Proteins; Sulfonamides; Thrombin | 2013 |
Argatroban for Treatment of Heparin-Induced Thrombocytopenia and Thrombosis in a Patient with Multiple Myeloma Undergoing Hemodialysis.
Topics: Aged, 80 and over; Anticoagulants; Antithrombins; Arginine; Dalteparin; Female; Humans; Multiple Myeloma; Partial Thromboplastin Time; Pipecolic Acids; Renal Dialysis; Sulfonamides; Thrombocytopenia; Venous Thrombosis | 2016 |
Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia.
Topics: Aged; Antithrombins; Arginine; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Pipecolic Acids; Pyrazoles; Pyridones; ST Elevation Myocardial Infarction; Sulfonamides; Thrombocytopenia; Thrombosis | 2020 |